Alliance A021602: Phase III, Double Blinded Study of Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) After Progression on Prior Therapy (CABINET)
- Citation:
- Ann Oncol vol 34 (suppl 2) S1292, abstr LBA53
- Meeting Instance:
- ESMO 2023
- Year:
- 2023
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 4434
- Pharmas:
- Exelixis
- Grants:
- U10CA180821, U10CA180882; U10CA180820 (SWOG), U10CA180868 (NRG), U10CA180888 (SWOG)
- Corr. Author:
- Authors:
- Jennifer A Chan Susan Geyer Fang-Shu Ou Michael Knopp Spencer Behr Tyler Zemla Jared Acoba Ardaman Shergill Edward M Wolin Thorvardur R Halfdanarson Nikolaos A Trikalinos Bhavana Konda Namrata Vijayvergia Arvind Dasari Jonathan R Strosberg Elise C Kohn Matthew H Kulke Eileen M O'Reilly Jeffrey A Meyerhardt
- Networks:
- CA824, FL065, HAWAII, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY016, LAPS-OH007, NY021
- Study
- Alliance-A021602
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: